Experimental cancer drug gets extended testing in patients out of options
NCT ID NCT05508334
First seen Jan 10, 2026 · Last updated Apr 04, 2026 · Updated 15 times
Summary
This study provided continued access to the experimental drug RC88 for patients with advanced solid tumors who had already participated in earlier research. The main goal was to further assess the safety and side effects of RC88 treatment. Researchers also measured how well the drug worked against cancer and how long its effects lasted in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Remegen
Beijing, Beijing Municipality, China
-
Remgenen
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.